(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.
Shares in IQ-AI were trading 8.3% higher at 3.90 pence on Tuesday morning in London.
The trial is studying the safety and efficacy of oral gallium maltolate, or GaM, in patients with recurrent or refractory glioblastoma. IQ-AI's subsidiary Imaging Biometrics LLC is conducting the study.
The St Helier, Jersey-based medical services firm said that of 14 patients evaluable for oral GaM treatment, three had achieved a median progression-free survival exceeding 180 days as of November 30, with one person on treatment for over one year.
"This compares favourably with the 1.5 to six-month range historically reported for progression-free survival in this population of relapsed GBM," IQ-AI explained. Following recurrence of GBM, patients have a median overall survival rate of two to nine months.
"We are encouraged by the favorable safety and tolerability profile at all dose levels," said the study's Chair Christopher Chitambar. "Other pre-clinical studies have been conducted that demonstrate that oral [GaM] may prove to be a viable treatment alternative across multiple solid tumours as well."
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Iq-ai Ltd (IQAI)